Related references
Note: Only part of the references are listed.Cyclophosphamide-induced severe acute hepatitis in a rheumatic disease: case-based review
Dondu Uskudar Cansu et al.
RHEUMATOLOGY INTERNATIONAL (2019)
Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus
Wenying Shu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients A hospital-based observational study
Daiki Tsuji et al.
MEDICINE (2016)
Cyclophosphamide treatment-induced leukopenia rates in ANCA-associated vasculitis are influenced by variant CYP450 2C9 genotypes
Jan Henrik Schirmer et al.
PHARMACOGENOMICS (2016)
Post-Transplant High-Dose Cyclophosphamide for the Prevention of Graft-versus-Host Disease
Ahmad Samer Al-Homsi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation
Ibrahim El-Serafi et al.
PLOS ONE (2015)
Cytochrome P450-activated prodrugs
Paul R Ortiz de Montellano
Future Medicinal Chemistry (2013)
Low-dose cyclophosphamide-induced acute hepatotoxicity
S. Ravih Subramaniam et al.
AMERICAN JOURNAL OF CASE REPORTS (2013)
The P450 oxidoreductase*28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients
Hylke de Jonge et al.
PHARMACOGENOMICS (2011)
Genotype Frequencies of Selected Drug Metabolizing Enzymes and ABC Drug Transporters among Breast Cancer Patients on FAC Chemotherapy
Nasir Ali Afsar et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2010)
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
J. Bray et al.
BRITISH JOURNAL OF CANCER (2010)
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia
V. Rocha et al.
LEUKEMIA (2009)
Cyclophosphamide and cancer: golden anniversary
Ashkan Emadi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Influence of polymorphisms of drug metabolizing enzymes (CYP2136, CYP2C9, CYPX19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide
Corine Ekhart et al.
PHARMACOGENETICS AND GENOMICS (2008)
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients
Miki Nakajima et al.
PHARMACOGENETICS AND GENOMICS (2007)
Intra- and inter-ethnic differences in the allele frequencies of cytochrome P4502B6 gene in Chinese
Su Guan et al.
PHARMACEUTICAL RESEARCH (2006)
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy
M de Jonge et al.
BRITISH JOURNAL OF CANCER (2006)
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies
HJ Xie et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Clinical pharmacokinetics of cyclophosphamide
ME de Jonge et al.
CLINICAL PHARMACOKINETICS (2005)
Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis
K Takada et al.
ARTHRITIS AND RHEUMATISM (2004)
Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation
GB McDonald et al.
BLOOD (2003)
Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli
TM Ishimoto et al.
PHARMACOGENETICS (2002)
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
T Lang et al.
PHARMACOGENETICS (2001)
Share Paper
